Pancreatic Cancer Research

ResearcherSun Yat-sen UniversityActive in the last 2 years

Jiachun Su

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8445-4901; OpenAlex author ID A5075996834. Sources: OpenAlex.

Their work

Papers
12 (first author 3, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
34
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: 4 papers · 2022: none · 2023: 4 papers · 2024: none · 2025: 2 papers · 2026: 1 paper

Papers 12

  1. NSUN6 deficiency drives immune suppression in pancreatic cancer via the KDM5A-CCL2-macrophage axis. Last author DOI 10.1136/gutjnl-2025-336541↗
  2. Identification of novel plasma proteins as promising noninvasive biomarker for early diagnosis and surveillance of pancreatic ductal adenocarcinoma. First author DOI 10.1007/s00535-025-02252-w↗
  3. Correction: Identification of novel plasma proteins as promising noninvasive biomarker for early diagnosis and surveillance of pancreatic ductal adenocarcinoma First author DOI 10.1007/s00535-025-02274-4↗
  4. LncRNA BCAN-AS1 stabilizes c-Myc via N6-methyladenosine-mediated binding with SNIP1 to promote pancreatic cancer. First author DOI 10.1038/s41418-023-01225-x↗
  5. CSTF2 mediated mRNA N6-methyladenosine modification drives pancreatic ductal adenocarcinoma m6A subtypes. Co-author DOI 10.1038/s41467-023-41861-y↗
  6. Super-enhancer RNA m6A promotes local chromatin accessibility and oncogene transcription in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41588-023-01568-8↗
  7. N 6-methyladenosine Modification of FZR1 mRNA Promotes Gemcitabine Resistance in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-22-3346↗
  8. LINC00842 inactivates transcription co-regulator PGC-1α to promote pancreatic cancer malignancy through metabolic remodelling. Co-author DOI 10.1038/s41467-021-23904-4↗
  9. N6 -methyladenosine-Mediated Upregulation of WTAPP1 Promotes WTAP Translation and Wnt Signaling to Facilitate Pancreatic Cancer Progression. Co-author DOI 10.1158/0008-5472.can-21-0494↗
  10. Inflammatory cytokine-regulated tRNA-derived fragment tRF-21 suppresses pancreatic ductal adenocarcinoma progression. Co-author DOI 10.1172/jci148130↗
  11. Genome-wide identification and characterization of circular RNA m6A modification in pancreatic cancer. Co-author DOI 10.1186/s13073-021-01002-w↗
  12. Excessive miR-25-3p maturation via N6-methyladenosine stimulated by cigarette smoke promotes pancreatic cancer progression. Co-author DOI 10.1038/s41467-019-09712-x↗

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jialiang Zhang · 12 shared papers, 2019–2026 · strength 1.65
  2. Lingxing Zeng · 10 shared papers, 2021–2026 · strength 1.48
  3. Xudong Huang · 9 shared papers, 2021–2026 · strength 1.19
  4. Jian Zheng · 9 shared papers, 2019–2023 · strength 1.02
  5. Dongxin Lin · 9 shared papers, 2019–2023 · strength 1.02
  6. Rufu Chen · 8 shared papers, 2019–2023 · strength 0.89
  7. Shaoping Zhang · 7 shared papers, 2021–2023 · strength 0.86
  8. Ziming Chen · 4 shared papers, 2023–2026 · strength 0.76
  9. Zilan Xu · 4 shared papers, 2023–2026 · strength 0.76
  10. Chunling Xue · 4 shared papers, 2023–2026 · strength 0.76
  11. Yanfen Zheng · 7 shared papers, 2019–2023 · strength 0.75
  12. Ying Ye · 6 shared papers, 2019–2023 · strength 0.64
  13. Quanbo Zhou · 4 shared papers, 2023 · strength 0.56
  14. Zhixiang Zuo · 5 shared papers, 2019–2023 · strength 0.55
  15. Junge Deng · 5 shared papers, 2021–2023 · strength 0.54
  16. Rui Li · 4 shared papers, 2021–2023 · strength 0.52
  17. Guandi Wu · 4 shared papers, 2021–2023 · strength 0.44
  18. Lusheng Wei · 4 shared papers, 2021 · strength 0.40
  19. Shuang Liu · 2 shared papers, 2025 · strength 0.39
  20. Lu Zheng · 2 shared papers, 2025 · strength 0.39
  21. Ling Pan · 4 shared papers, 2019–2021 · strength 0.36
  22. Xu Che · 3 shared papers, 2019–2021 · strength 0.26
  23. Chen Hsuan Wu · 3 shared papers, 2019–2021 · strength 0.26
  24. Qi Zhou · 1 shared paper, 2026 · strength 0.23
  25. Chengfeng Wang · 2 shared papers, 2019–2021 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.